We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.

The U.S. Food and Drug Administration first approved Jivi® in August 2018 for the treatment of hemophilia A in adolescents and adults 12 years of age and over, including for prophylactic, on-demand and perioperative management of bleeding.

This “Notice of Intent” is being released now by NHLBI to provide eligible applicants ample time to develop competitive applications for submission in 2020.

NHF’s Dawn Rotellini Elected to WFH Board of Directors

The appointment is effecitve as of December 5, 2019.

Sangamo and Pfizer Announce Progress in Gene Therapy Trial at ASH

Pfizer and Sangamo presented their gene therapy updates in a poster presentation during the 61st Annual Meeting of the American Society of Hematology in Orlando, Florida.

These educational activities are designed specifically for healthcare providers who may be new to this field or who function outside the hemophilia treatment center network, including primary care physicians, obstetrician/gynecologists, nurse/nurse practitioners, dentists, oral surgeons and other allied professionals.

Subscribe to Our Newsletter

Fill in the fields below to receive our email newsletter.


OUR ADVERTISERS